# Three-Dimensional Structure-Activity Relationships and Receptor Mapping of  $N_1$ -Substituents of Quinolone Antibacterials<sup>1</sup>

Masateru Ohta\* and Hiroshi Koga

*Fuji-gotemba Research Laboratries, Chugai Pharmaceutical Company, Ltd., 135, 1-Chome Komakado, Gotemba-shi, Shizuoka, 412, Japan. Received November 21, 1989* 

Quantitative structure-activity relationships for quinolone antibacterials have been previously examined and a steric parameter  $L$  for the N<sub>1</sub>-substituents found to be important in QSAR equations. But some compounds for which previous QSAR equations could not predict the activity have appeared recently. In this study, conformations of a variety of N<sub>1</sub>-substituents of quinolone antibacterials were analyzed by a molecular modeling method. An active conformation of each of the compounds was estimated with information of the energy profile calculated by molecular orbital methods and of its biological activity. A model of a receptor corresponding to the  $N_1$ -substituents was constructed by superposing van der Waals volumes of active conformer of highly active compounds. As a result of these conformational analyses and receptor mapping, it is proposed that there are two different optimum volumes for increasing the activity of quinolone antibacterials and two unfavorable regions for reducing the activity. It is suggested that the steric parameter  $L$  which appeared in previous QSAR equations corresponds to one of the optimum volumes of the proposed receptor model. With this receptor model, a relation between structure and activity of the compounds, including those mispredicted compounds in previous QSAR equations, is able to be rationalized qualitatively and elegantly. We believe that this receptor model is useful for a prediction of the activity of compounds not yet synthesized as well as for designing new quinolone antibacterials.

Norfloxacin (NFLX, 1), which was synthesized by one of the present authors (Koga<sup>2</sup>), opened a new age not only in quinolone antibacterials but also in oral antiinfectives. The appearance of NFLX expanded the clinical uses of quinolones greatly. NFLX is superior to the earlier quinolones in that it has a potent activity against Grampositive bacteria as well as Gram-negative bacteria (including *Pseudomonas aeruginosa),* a low incidence of resistant bacteria, an incomplete cross-resistance against nalidixic acid resistant bacteria, an oral effectiveness against systemic infections, metabolic stability, and a low oral toxicity.<sup>3</sup> After NFLX was discovered, many related compounds including its bioisoster, enoxacin (2), have been developed and quite a few have been marketed<sup>2,4</sup> (Table I). These compounds are commonly called "new quinolones" or "fluoroquinolones" because they share a common 6-fluoro-7-aminoquinolone structure.



Koga<sup>2b,c</sup> previously examined the quantitative structure-activity relationships (QSAR) for a set of 71 compounds shown as a generic structure 3. From the statistical point of view, one of the best correlations is shown as eq 1. In this equation, the minimum inhibitory concentration

$$
\log (1/\text{MIC}) = -0.362L(1)^2 + 3.036L(1) - 2.499E_8(6)^2 - 3.345E_8(6) - 0.205[\sum \pi (6,7,8)]^2 - 0.485\sum \pi (6,7,8) + 0.986I(7) - 0.734I(7N-CO) - 1.023B_4(8)^2 + 3.724B_4(8) - 0.681\sum F(6,7,8) - 4.571 (1)
$$

$$
(n = 71, s = 0.274, r = 0.964, r^2 = 0.929, F = 70.22)
$$

in mol/L (MIC) against *Escherichia coli* NIHJ JC-2 is used for biological activity. L(l) is Verloop's STERIMOL parameter representing the length  $(L)$  of the substituent at the position 1.  $E<sub>s</sub>(6)$  represents the Taft-Kutter-Hansch steric parameter  $(E_s)$  of R<sub>6</sub>.  $\sum \pi(6,7,8)$  stands for the sum of the hydrophobic constant  $(\pi)$  of the R<sub>6</sub>, R<sub>7</sub>, and  $R<sub>8</sub>$  substituents. This hydrophobic parameter seems to be related mainly with the transport of compounds into the active site.  $I(7)$  is an indicator variable equal to zero when the 7-substituent is hydrogen and expressed as unity when it is not.  $I(7N-CO)$  is another indicator variable which is expressed as unity when there is a carbonyl group within the 7-amino substituent moiety, and zero when there is not.  $B_4(8)$  is the STERIMOL parameter and represents the maximum width of  $R_8$ . It seems that the direction of the maximum width of the  $R_8$  substituent  $(B_4(8))$  corresponds to the side opposite to the  $R_1$  substituent ( $R_7$  side) because the steric interaction between the  $R_1$  and  $R_8$  substituent was able to occur.  $\sum F(6,7,8)$  is the sum of the Swain-Lupton-Hansch inductive electronic parameter *(F)* of the 6-, 7-, and 8-substituents. Equations that were statistically almost equivalent or less significant were also formulated annost equivalent or less significant were also formulated<br>with oither  $\pi(T)$  for the hydrophobicity of only the R with either  $\pi(i)$  for the hydrophobicity of only the  $N_7$ substituent or  $\log P$  for the whole molecule instead of the ny arophobic parameter  $\sum \pi(0, t, \delta)$  in eq. 1. Equation 1 indicates clearly that the steric factor of the  $R_1, R_6$ , and  $R<sub>8</sub>$  substituents are important for the activity of the quinolone antibacterials. It also suggests that compounds having an  $R_1$  substituent with a length  $(L)$  of approximately 4.2 Å (e.g., ethyl, vinyl, methoxy, methylamino, fluoroethyl, cyclopropyl), an R<sub>6</sub> substituent with an  $E_s$ value of approximately -0.65 (e.g., fluoro, chloro, oxygen, nitrogen), an  $R_7$  substituent with a  $\pi$  value of approximtely  $-1.4$  [or a  $\sum \pi(6,7,8)$  value of approximately  $-1.2$  or a log P value of approximately  $-1.0$ ] (e.g., piperazinyl, aminopiperidinyl, aminopyrrolidinyl as the  $R_7$  substituent), and an  $R_8$  substituent with a width  $(B_4)$  of approximately 1.8 Å (e.g., fluoro, chloro, bromo, methyl, methylene, oxygen)

<sup>(1)</sup> This work was presented at the 15th Symposium on Structure-Activity Relationships, Nov. 6-8,1987, Tokyo: *Abstract of papers;* pp 338-341.

<sup>(2) (</sup>a) Koga, H.; Itoh, A.; Murayama, S.; Suzue, S.; Irikura, T. *J. Med. Chem.* 1980, *23,* 1358. (b) Koga, H. In *Structure-Activity Relationships*—*Quantitative Approaches; Applications to Drug Design and Mode-of-Action Studies;* Fujita, T., Ed.; Nankodo: Tokyo, 1982; pp 177-202. (c) Fujita, T. In *Drug Design: Fact or Fantasy;* Jolles, G., Wooldridge, K. R. H., Eds.; Academic Press: New York, 1984; p 19.

<sup>(3)</sup> Holmes, B.; Brogden, R. N.; Richards, D. M. *Drugs* 1985, *30,*  482.

<sup>(4)</sup> Fernandes, P. B.; Chu, D. T. W. *Ann. Rep. Med. Chem.* 1988, *23,* 133 and references therein.

**Table I.** Fluoroquinolones



could exhibit an activity comparable to or more potent than NFLX. These predictions have been proved by further syntheses and the biological evaluations of such compounds as, e.g., AM-833 (4), ofloxacin (5), amifloxacin (6), ciprofloxacin (7), CI-934 (8), AM-1091 (9), and PD117558 (10) (Table I).<sup>4</sup>

Recently, Chu et al.<sup>5a</sup> and Narita et al.<sup>5b</sup> reported the synthesis of l-(p-fluorophenyl)fluoroquinolone 11, which possesses a potent activity comparable to that of NFLX [original value of  $log(1/MIC)$  (mol/L) of NFLX against *E. coli* **NIHJ** JC-2 is 6.629].<sup>2</sup> Equation 1 predicts a much lower activity for this compound (11) and the calculated value of log (1/MIC) (mol/L) against *E. coli* NIHJ JC-2 for compound 11 is 3.82. Simple aromatic groups as the Ni-substituent of the quinolones were already cited in the earlier report.<sup>6</sup> Equation 1 was derived from only simple alkyl groups, not including any aryl groups, with small variations in  $R_1$ . This appears to be the reason for the misprediction of the activity of  $N_1$ -arylquinolones like compound 11. If the structure and activity of these  $N_1$ arylquinolones are included in the analysis, the steric effect of the  $N_1$ -substituent seems to be more complex than the

- (5) (a) Chu, D. T. W.; Fernandes, P. B.; Claiborne, A. K.; Pihuleac, E.; Nordeen, C. W.; Maleczka, R. E., Jr.; Pernet, A. G. *J. Med. Chem.* **1985,** *28,* 1558. (b) Narita, H.; Konishi, Y.; Nitta, J.; Nagaki, H.; Kobayashi, Y.; Watanabe, Y.; Minami, S.; Saikawa, I. *Yakugaku Zasshi* **1986,** *106,* 795.
- (6) Albrecht, R. *Prog. Drug Res.* 1977, *21,* 9.
- (7) Atarashi, S.; Yokohama, S.; Yamazaki, K.; Sakano, K.; Imamura, M.; Hayakawa, I. *Chem. Pharm. Bull.* **1987,** *35,* 1896.
- (8) Wentland, M. P.; Bailey, D. M.; Cornet, J. B.; Dobson, R. A.; Powles, R. G.; Wagner, R. B. *J. Med. Chem.* **1984,** *27,* 1103. (9) Wolfson, J. S.; Hooper, D. C. *Antimicrob. Agents Chemother.*
- **1985,** *28,* 581.
- (10) Enomoto, H.; Kise, M.; Ozaki, M; Kitano, M.; Morita, I. Japanese Patent Kokai 103393, 1983; *Chem. Abstr.* **1983,** *98,*   $3877w.$
- (11) Matsumura, S.; Kise, M.; Ozaki, M.; Tada, S.; Kazuno, K.; Watanabe, H.; Kunimoto, K.; Tsuda, M. Japanese Patent Kokai 136588, 1982; *Chem. Abstr.* **1983,** *98,* 53877u).

case of simple alkyl groups where only the length factor of the  $N_1$ -substituent appeared in eq 1. In this report, we analyzed the conformation of the compounds, including the  $N_1$ -arylquinolones, by using a systematic search method, and reexamined the steric effect of the  $N_1$ -substituents of the quinolone antibacterials precisely. We attempted to rationalize the relationship between biological activity and the three-dimensional structure of the  $N_1$ substituent and create a receptor map corresponding to the  $N_1$ -substituent of quinolones 3. We also tried to explain the relationship between eq 1 and a receptor mapping for the Nj-substituent.

#### **Compounds and Biological Activity**

The compounds and biological activity analyzed are listed in Table II. The MIC against *E. coli* was chosen as the biological activity because it is one of the representative Gram-negative bacteria and, in the case of the quinolone antibacterials, the activity against *E. coli* roughly parallels the activity against other Gram-negative bacteria.<sup>2,4</sup> The relative activity of each compound compared to the activity of the standard drug, NFLX (1), was calculated because all of these biological assays were not always tested under the same conditions. The compounds were classified into five groups according to their relative activity as shown in Table II. In this data set, the class 1 compounds have the highest biological activity and the range of the relative activity of the class 1 compounds is from 4 to 0.5. The class 5 compound has the lowest activity and the relative activity of this class is less than or equal to  $\frac{1}{2000}$ . The range of the overall activity variation covers a range almost 8000-fold.

## **Molecular Modeling**

A systematic search method was used for the analysis of conformational aspects of these compounds. The three-dimensional structure of the quinolone ring was constructed from the X-ray data of oxolinic acid  $(3: R<sub>1</sub>)$  $= C_2H_5$ ,  $R_6$ ,  $R_7 = -OCH_2O^-$ ,  $R_8 = H$ ).<sup>12</sup> The structure of the substituents of each compound was taken from the fragment library of a SYBYL system.<sup>13</sup> Original models of each compound were built with standard bond lengths and angles. The energy of each compound was then minimized with molecular mechanics with a Tripos force field.<sup>13</sup> These structures were used as original coordinates for further energy optimization using quantum mechanics. The 7-unsubstituted 6-fluoroquinolones (3:  $R_6 = F$ ,  $R_7 =$ H) were used as the model structure for the conformational analysis because the conformation of the  $N_1$ -substituents was not affected by the 7-substituents within compounds analyzed here, and the energy calculation was easier when the 7-position was unsubstituted. Conformations were preliminarily examined by the SEARCH routine in the SYBYL system. Conditions for preliminary search were defined so that all rotatable bonds within  $N_1$ -substituents were rotated by an increment of 5°. Conformations were then analyzed by using such molecular orbital (MO) methods as CNDO/2<sup>14</sup> and AM1.<sup>15</sup> The Gaussian 82 (STO-3G)<sup>16</sup>

- (12) Cygler, M.; Huber, C. P. *Acta Crystallogr.* **1985,** *C41,* 1052. (13) SYBYL Molecular Modeling System; Tripos Associates: St. Louis.
- (14) Pople, J. A.; Segal, G. A. *J. Chem. Phys.* **1966,** *44,* 3289.
- (15) Dewar, M. J. S.; Zoebisch, E. G.; Healy, E. F.; Stewart, J. J. P. *J. Am. Chem. Soc.* **1985,** *107,* 3902.
- (16) Brinkley, J. S.; Frish, M. J.; DeFrees, D. J.; Raghavachari, K.; Whiteside, R. A.; Schlegel, H. B.; Fluder, E. M.; Pople, J. A. *Gaussian 82;* Carnegie Mellon University, Pittsburgh, PA, 1983.

# Table II. Relative Activity of Fluoroquinolones





<sup>a</sup> Relative activities compared to that of norfloxacin (1) are in parentheses.

ethyl, cyclopropyl, and phenyl as the N<sub>1</sub>-substituent. possible to examine the differences between the MO pro-

program was also used for analyzing compounds having  $\qquad \quad$  the energy profiles for various conformations as far as Three MO methods were used since we wanted to know cedures in finding the energy minimum. In the MO



**Figure 1.** Rotational energy map of  $N_1-R_1$  bond of the 1cyclopropyl compound 35: (A) energy curve calculated by Gaussian 82 ( $\Box$ ), (B) energy curve calculated by AMI ( $\blacklozenge$ ), (C) energy curve calculated by  $CNDO/2$  ( $\blacksquare$ ).

analysis, all rotatable bonds in  $N_1$ -substituents were rotated by a 15° increment and then scanned with a 5° increment around the local minimum. After the determination of the minimum-energy conformation of each of the N<sub>1</sub>-substituents, a piperazinyl or an  $N$ -methylpiperazinyl group was attached at position 7 of the model compounds and their conformation was optimized by using the AMI program.

The "total" occupied volume of the  $N_1$ -substituents for each of the compound classes was calculated by superposing the van der Waals volumes of the active conformer of the  $N_1$ -substituents of each of the compound classes using the MVOLUME routine in the SYBYL system. The difference in the total volume between the different classes was calculated by subtracting the total volume for all of the more active compound class from that of the less active compound class.

# **Results and Discussion**

The procedure in defining the "active" conformation essential for the activity is very important in discussing the steric effect of the substituents.

Conformation analysis was started from  $N_1$ -cyclopropyl compound 35. Ciprofloxacin (7), the 7-piperazinyl derivative of compound 35, has the highest activity among the  $N_1$ -substituted quinolones in this analysis (Table II) and the activity relative to NFLX (1) is equal to 4. The  $N_1-R_1$ bond of the  $N_1$ -cyclopropyl derivative 35 was rotated from 0 ° to 360° and the energy of each conformer was calculated as described above (Figure 1). After this analysis two energy minima were found. There was no substantial differences between the results of the three MO methods as shown in Figure 1. One of the energy minima corresponds to the conformation where the cyclopropyl moiety is above the plane of the quinolone ring (dihedral angle  $2-1-1'-3'$  is equal to  $110^{\circ}$ ), and the other to that below the plane (dihedral angle  $2-1-1'-3' = -40^{\circ}$ ). There was no energy difference between the two. With only this information, it was impossible to determine which is the active conformation. Therefore a conformation analysis of ofloxacin (5), which has a fairly rigid structure and a potent activity, was carried out to obtain more insight into the active conformation of the  $N_1$ -cyclopropyl. Ofloxacin (5) has two optical isomers and it has been reported that the activity of the S isomer  $[5(S)]$  is higher than that of the activity of the *S* isomer [ $\sigma(S)$ ] is higher than that of the<br>*R* isomer [ $\sigma(S)$ ] <sup>7</sup> The fact that the *S* isomer is more active than the *R* isomer is also reported for the structurally than the *R* isomer is also reported for the structurally similar compound S-25930 (3:  $R_0 = F_0 R_1 = C H_0 R_2 R_3$ similar compound S-20930 (3:  $R_6 = r$ ,  $R_7 = C H_3$ ,  $R_8$ ,  $R_1$ <br>= -CH<sub>2</sub>CH<sub>2</sub>CH(CH<sub>2</sub>)-)<sup>17</sup>. The conformation analysis of

the model compound [3:  $R_6 = F$ ,  $R_7 = H$ ,  $R_8$ ,  $R_1 =$  $-{\rm OCH_2CH(CH_3)-}$  taken from compound 5 showed that the S isomer has two stable conformations without significant energy difference (the energy difference is 0.03 kcal/mol with the AMI method). One of the stable conformers is that where the branched methyl moiety is perpendicular to the plane of the quinolone ring (dihedral angle  $2-1-1^{\prime}-2^{\prime} = 80^{\circ}$  and the other is that where it is fairly inclined to the plane of the ring (dihedral angle  $2-1-1'-2' = 32^{\circ}$ . It seemed that, in the overall shape of the  $N_1$ -substituent of these two compounds, the latter conformer of  $5(S)$  resembles the conformer of the  $N_1$ cyclopropyl compound 35 well if the  $N_1$ -cyclopropyl group locates above the plane of the quinolone ring. Consequently, the matched conformers of compounds  $5(S)$  and 7 were selected as active conformers for the  $N_1$ -substituents (Figure 2). This selected active conformer of *5{S)* was also the lowest energy conformer.

Next, the active conformer of the model compound (3:  $R_6 = F$ ,  $R_7 = R_8 = H$ ,  $R_1 = CH_2CH_3$ ) taken from norfloxacin 1, was examined. There were three energy minima which correspond to the states in which the  $N_1$ -ethyl locates above (dihedral angle  $2-1-1'-2'$  is equal to 100°), below  $(2-1-1^2-2^r = -100^{\circ})$ , and parallel  $(2-1-1^2-2^r = 0^{\circ})$ to the quinolone ring. The energy difference between the "above" conformer  $(2-1-1'-2') = 100^{\circ}$  and the "parallel" conformer  $(2-1-1^2-2^2 \approx 0^{\circ})$  is 0.47 kcal/mol with the AM1 method, and there was no energy difference between the "above" and "below" conformers. The conformation in which the  $N_1$ -ethyl was above the quinolone ring was selected as the active conformer because, among three conformers, it resembled the active conformation of the  $N_1$ -substituents of  $5(S)$  and 7 well. This selected active conformer of NFLX (1) was also the lowest energy conformer.

In the case of the  $N_1$ -phenyl derivative (3:  $R_1 = C_6H_5$ ,  $R_6 = F$ ,  $R_7 = R_8 = H$ ), the conformational search showed that there were two energy minima which correspond to the angle between the quinolone and the phenyl ring are 70° and 110° and there was no difference in energy between the two conformers. The latter conformer was selected as the active conformer of compound 24 by a comparison of the shapes of the  $N_1$ -substituent of the two conformers with the active conformations of compounds 1, *5(S),* and 7 (Figures 2 and 6). The active conformation of the other compounds was defined in a similar way so that, among the low-energy conformers, the conformer which resembles the active conformer of the  $N_1$ -substituents of highly active compounds (1, *5(S),* and 7) was selected (Figures 2-4 and 6-11). The torsion angles of the active conformer of each of the  $N_1$ -substituents are shown in Table III.

For the  $N_1$ -benzyl derivative (22), the active conformation was selected as shown in Figure 6. There were a number of low-energy conformers for the  $N_1$ -benzyl substituent. Among these low-energy conformers, there was a conformer which occupies a region close to the meta position of the  $N_1$ -phenyl in compound 24. As described later, the region close to the meta position of the  $N_1$ -phenyl in compound 24 resulted in a detrimental effect on the activity (Figure 6). Since the  $N_1$ -benzyl compound (22) is a fairly active class 2 compound, the active conformation of the  $N_1$ -benzyl was selected so that this substituent did not occupy the detrimental region. This selected con-

<sup>(17)</sup> Gerster, J. I.; Rolfing, S. R.; Pecore, R. M.; Winandy, R. M.; Stern, R. M; Landmesser, J. E.; Olsen, R. A.; Gleason, W. B. *J. Med. Chem.* 1987, *30,* 839.



Figure 2. Stereoview of the superposition of the proposed active conformers of 1 (green),  $5(S)$  (yellow), 7 (blue), and 11 (orange).



Figure 3. Stereoview of the superposition of the proposed active conformers of 6 (yellow), 13 (green), 15 (orange), and 16 (cyan).



Figure 4. Stereoview of the superposition of the proposed active conformers of 12 (green), 14 (red), 17 (yellow), and 18 (violet).



Figure 5. Stereoview of the total volume (orange) of the  $N_1$ -substituents of class 1 compounds.



Figure 6. Stereoview of the superposition of the proposed active conformers of 19 (green), 22 (yellow), *5(R)* (orange), and 24 (violet) and the difference (orange) in the total volume between the set of 19, 22, *5(R),* and 24 and class 1 compounds.

former of compound 22 was also the lowest energy conformer.

For the  $N_1$ -propyl, -allyl, -(hydroxyethyl), and -[(dimethylamino)ethyl] substituents in compounds 19-21 and 30, there were two plausible, low-energy conformers: one is the extended form and the other the bent form. The former was selected as the active conformation in this analysis because the most significant factor for the effect of  $N_1$ -substituents was represented by the quadratic function of the length *L* in eq 1, and this suggested that these substituents interact with the receptor in their extended form (Figures 6-9). These selected conformers of compound 19-21 and 30 were also the lowest energy conformers.

The active conformers of the class 1 compounds were superposed by matching the corresponding atoms in the quinolone ring of each molecule. The total occupied volume for the N,-substituents of superposed "active"



**Figure 7.** Stereoview of the superposition of the proposed active conformers of 20 (orange), 23 (green), 25 (blue), and 27 (yellow) and the difference (orange) in the total volume between the set of 20, 23, 25, and 27 and class 1 compounds. Since phenyl rings of the N<sub>1</sub>-substituents of compound 25 and 27 overlap, it looks white.  $N_1$ -Methyl of compound 23 and  $N_1$ -allyl of compound 20 also overlap and the N-methyl looks white or yellow-green.



**Figure** 8. Stereoview of the superposition of the proposed active conformers of 21 (green), 26 (yellow), 28 (violet), and 29 (blue) and the difference (orange) in the total volume between the set of 21, 26, 28, and 29 and class 1 compounds.



**Figure 9.** Stereoview of the superposition of the proposed active conformers of 30 (green), 31 (yellow), and 32 (cyan) and the difference (orange) in the total volume between the union of compound 30, 31, and 32 and the union of class 1 and class 2 compounds.



**Figure 10.** Stereoview of the proposed active conformer of 33 and the difference (orange) in the total volume between compound 33 and the union of class 1, 2, and 3 compounds.



**Figure 11.** Stereoview of the proposed active conformer of 34 and the difference volume (orange) between compound 34 and the total of class 1, 2, 3, and 4 compounds.

molecules was then calculated to estimate the receptor model (active volume) of quinolone antibacterials (Figure 5). This model represents an estimated optimum volume for the Nj-substituent of quinolone antibacterials when it interacts with its receptor and can be used for verification of the biological activity of quinolone antibacterials and, further, for prediction of the activity of compounds not yet synthesized. If a compound fits well with this receptor model, it is expected to have high activity. This receptor model should be corrected whenever new information about the quinolone receptor or novel  $N_1$ -substituents and their biological activity is gained.

In the next step, the difference in occupied volume of the  $N_1$ -substituents between class 1 and the less active class 2 compounds was calculated by subtracting the total occupied volume of class 1 from that of class 2 (Figures 6-8). The total occupied volume of the class 2 compounds was calculated by procedures similar to the those for the class 1 compounds. The increase in occupied volume compared to the class 1 receptor model was thought to make the activity of the class 2 compounds lower. The region representing the difference between two occupied volumes seems to be the region where a steric repulsion occurs between the receptor wall and the  $N_1$ -substituent of the class 2 compounds. Figures 6-8 show that the o-methyl (26), m-(methyleneoxy) (29), p-methyl (28), and p-chloro (27) substituents of the  $N_1$ -phenyl and  $N_1$ -benzyl (22) compounds occupy extra regions not occupied by the class 1 compounds.

On the contrary, it seemed that the  $p$ -hydrogen of the Nj-phenyl **(24-26)** is somewhat too small to fit the important region, the p-hydroxy or p-fluoro region of the  $N_1$ -phenyl group, of the receptor model. The p-hydroxy or p-fluoro region of the  $N_1$ -phenyl group is considered to be important for the activity because p-hydroxyphenyl (15) and p-fluorophenyl (11) compounds have the highest activity (class 1) among the substituted  $N_1$ -phenyl derivatives, and the compounds which do not have an optimum volume around this region (e.g. compounds 27 and 28 are too large and compounds **24-26** are too small) have lower activity.

It seems that the  $N_1$ -methyl (23) is also somewhat too small to fit the other important region, which corresponds to the  $N_1$ -cyclopropyl region of 7, of the receptor model because compound 7, having  $N_1$ -cyclopropyl, has the highest activity among the compounds analyzed here (as described above) and this region seems to correspond to the optimum value  $(4.2 \text{ Å})$  of  $L(1)$  in eq 1.

The terminal groups of the  $N_1$ -propyl (19), -allyl (20), and -(hydroxyethyl) (21) substituents occupy regions corresponding to the meta positions of the  $N_1$ -phenyl group as shown in Figures 6-8. These regions seem to reduce the activity of compounds **19-21.** Thus, the meta groups on the  $N_1$ -phenyl substituents could make the activity deteriorate. The methylene and branched methyl in the  $R_s, R_1$ cyclic moiety of *5(R)* are fixed below the plane of a quinolone ring as shown in Figure 6. This region below the quinolone ring seems to interfere with the binding of compound to the receptor and seems to cause a reduction of activity.

The difference of the total occupied volume of the  $N_1$ -substituents of the class 3 compounds from that of both the class 1 and 2 compounds is shown in Figure 9. This volume was calculated by subtracting the total occupied volume of both class 1 and class 2 from that of class 3. A still extra region is indicated to be occupied by the two *N*-methyls of the  $N_1$ -[(dimethylamino)ethyl] (30) and the bromine at the para position of the  $N_1$ -phenyl substituent

## *SAR and Mapping of Quinolones Journal of Medicinal Chemistry, 1991, Vol. 34, No. 1* 137

(32). These regions were thought to cause a further reduction of activity for compounds 30 and 32 compared to those of class 1 and 2 compounds. For the  $N_1$ -(m-fluorophenyl) derivative (31), the volume of the hydrogen at the para position is too small to fit the receptor wall as described in the case of compounds **24-26.** The region occupied by the m-fluorine brings a reduction of activity as described in the case of compounds **19-21.** These two factors seem to work synergistically and lower the activity of compound 31 to class 3.

Figure 10 shows the difference in the total occupied volume between the class 4 and class 1-3 compounds. This volume was calculated by subtracting the total occupied volume of all of the class 1-3 compounds from that of the class 4 compound. The new region occupied by the pmethoxy group of the  $N_1$ -phenyl (33) would probably be unfavorable to the relevant binding with the receptor more significantly than  $N_1$ -substituents of class 1-3 compounds are.

Finally, the difference in the total volume between the least active class 5 compound,  $N_1$ -(2,6-dimethylphenyl) derivative 34, and the class 1-4 compounds was examined (Figure 11). As you can see from Figure **11,** the region occupied by one of the o-methyl groups below the quinolone ring was thought to exert a fatal effect upon the activity.

These analyses bring new and important insights into three-dimensional structure-activity relationships for  $N<sub>1</sub>$ -substituents of quinolone antibacterials. We propose that there are two optimum regions for increasing the activity. One of the optimum regions corresponds to the region occupied by the  $N_1$ -cyclopropyl group above the plane of the quinolone ring. The other corresponds to the region occupied by fluorine and hydroxyl at the para position of the  $N_1$ -phenyl.

We also propose that there are two regions unfavorable to proper receptor binding and the occupancy of these regions leads to reduction in the activity. One of the unfavorable regions corresponds to the region below the plane of the quinolone ring and the other corresponds to the meta position of the  $N_1$ -phenyl group above the quinolone ring plane. The reasons the region corresponding to the meta position of the  $N_1$ -phenyl group above the quinolone ring plane causes a bad effect on the activity are as follows. For the  $N_1$ -alkyl series, for example,  $N_1$ -ethyl compound NFLX (1) is a class 1 compound and  $N_1$ -propyl (19), -allyl (20), and -(hydroxyethyl) (21), which occupy the position corresponding to the meta position of the  $N_1$ -phenyl substituent, are class 2 compounds. For the  $N_1$ -phenyl series,  $N_1$ -phenyl derivative 24 is class 2 and  $N_1$ -(m-fluorophenyl) derivative 31, which also has a fluorine at the meta position, is a class 3 compound. This reduction of activity arises from the occupancy of the unfavorable region. In these two different series of the  $N_1$ -substituent, the reduction of the activity occurred by occupancy of the same region. We conclude the region below the plane of the quinolone ring reduces the activity because, for example, for the N<sub>1</sub>-phenyl series,  $N_1$ -(2-methylphenyl) derivative 26 belongs to class 2 and the  $N_1$ - $(2,6$ -dimethylphenyl) derivative 34, of which the one of the methyl group occupies the region under the quinolone ring (Figure 11), has almost no activity. Additionally, compound *5(R)* is a class 2 compound and occupies an extra region, which is not occupied by class 1 compounds, below the quinolone ring (Figure 6). A modified receptor model based on these insights is shown in Figure 12. This model is created with the total volume occupied by the  $N_1$ -cyclopropyl group and the hydroxy group of the  $N_1$ - $(p$ -hydroxyphenyl, which

# **Table III.** Calculated Dihedgral Angles of Fluoroquinolones





Table **III** (Continued)



"Dihedral angle of this compound is defined in Figure 1.  $b \text{ C}$  Cis = 0.



**Figure 12.** Stereoview of the modified receptor model for N<sub>1</sub>-substituents of quinolone antibacterials.

correspond to two optimum regions as described above.

From the present receptor model, it is possible to rationalize why *L* (length) worked best as the steric parameter for  $N_1$ -substituents in the QSAR eq 1 and why eq 1 was unable to predict the activity of  $N_1$ -phenyl derivatives. The  $L(1)$  parameter in eq 1 has an optimum at 4.2 Å, corresponding to the length of cyclopropyl, ethyl, etc. Equation 1 shows that the activity of the compounds without **Nj-phenyl** substituents decreases as the *L* value changes toward either side of the optimum value. The situation does, in fact, explain the activity variations in these compounds in terms of the one-dimensional projection of the receptor model onto the L axis, and the optimum value of  $L$  corresponds to the important  $N_1$ cyclopropyl region of the receptor model. For example, methyl was too small to fit the receptor wall corresponding to  $N_1$ -cyclopropyl, but the *n*-propyl, allyl, hydroxyethyl,  $\omega$   $\alpha_1$ -cyclopropyl, but the *n*-propyl, anyl, nydroxyethyl, and benzyl extrude to the region uniavorable to proper receptor binding, which corresponds to the meta position of the  $N_1$ -phenyl. The terminal methyls of (dimethylamino)ethyl penetrate further into the unfavorable region. The receptor model in Figure 12 has two optimum volumes for increasing the activity as described above. The unfavorable region corresponding to the meta position of the  $N_1$ -phenyl exists above the plane of the quinolone ring. The  $N_1$ -substituents of the compounds which were used to derive eq 1 could be accommodated to various extents only in the optimum volume corresponding to  $N_1$ -cyclopropyl, and they could not reach the other optimum region corresponding to the para position of the  $N_1$ -phenyl. But  $N_1$ -phenyl derivatives can reach the other optimum region, the para position of  $N_1$ -phenyl, and no information of this important region was included in eq 1. These are the reasons eq 1 could not predict the activity of  $N_1$ -phenyl

derivatives. These things indicate, if one uses the steric parameter in the QSAR equation, that one must be careful with regard to the relation between a steric parameter and an active conformation.

Recently, Domagala et al.<sup>18</sup> reported a QSAR analysis for Nj-substituents of 1-substituted 7-[3-[(ethylamino) methyl]-l-pyrrolidinyl]-6,8-difluoro-l,4-dihydro-4-oxo-3 quinolinecarboxylic acids and that the electronic parameter (unsaturation parameter) was significant at a  $\geq 90\%$  level along with the STERIMOL parameters, different from our conclusions. However, the validity of the unsaturation factor remains to be elucidated. We are currently examining the three-dimensional QSAR for quinolone antibacterials based on our analysis, and the details will be discussed elsewhere.

## **Experimental Section**

The molecular models were built with the program SYBYL and a SYBYL standard fragment library.<sup>13</sup> Original coordinates of the models were taken from the crystallographic data of oxolinic acid.<sup>12</sup> The calculations of molecular mechanics,  $CNDO/2^{14}$  and AM1,  $^{15}$  were made on a VAX. The Gaussian 82<sup>16</sup> data were calculated on a Cray XMP/216. The conformations were examined on an Evans & Sutherland PS330 computer terminal using the program SYBYL. The figures were photographed directly from the screen with Kodak Ektachrome 100 HC film.

Acknowledgment. We thank Dr. S. Hata and I. Matsuura for their support and encouragement during this work. We wish to express our thanks to Dr. T. Fujita of Kyoto University for his valuable and helpful discussion, advice, and comments.

<sup>(18)</sup> Domagala, J. M; Heifetz, C. L.; Hutt, M. P.; Mich, T. F.; Nichols, J. B.; Solomon, M.; Worth, D. F. *J. Med. Chem.* 1988, *31,* 991.